Search Results - "Sitarou, M."

Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone by Telfer, Paul T, Warburton, Fiona, Christou, Soteroula, Hadjigavriel, Michael, Sitarou, Maria, Kolnagou, Anita, Angastiniotis, Michael

Get full text

Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004 by Telfer, P, Coen, PG, Christou, S, Hadjigavriel, M, Kolnakou, A, Pangalou, E, Pavlides, N, Psiloines, M, Simamonian, K, Skordos, G, Sitarou, M, Angastiniotis, M

“…Department of Paediatric Haematology and Oncology, St. Bartholomew's and The Royal London Hospitals NHS Trust, UK. paul.telfer@bartsandthelondon.nhs.uk…”
Get full text

PF785 CHANGING CAUSES OF MORTALITY IN TDT DURING THE ERA OF ORAL CHELATION THERAPY FROM 2000 TO 2018 by Telfer, P., Kountouris, P., Christou, S., Hadjigavriel, M., Sitarou, M., Kolnagou, A., Kleanthous, M.

“…Background: Heart disease due to transfusion iron overload has been previously reported as the predominant cause of death in transfusion dependent thalassaemia…”
Get full text